The total number of records retrieved from this search are 10. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2189	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result98% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2190	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result85% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2191	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2192	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result30% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2193	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.01 MOI	In-vitro result20% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2194	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result85% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2195	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2196	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2197	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro result10% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2198	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineNPEC2/Bm1	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayX-gal staining and MTT assay	In-vitro virus concentration0.1 MOI	In-vitro resultAll cells was dead after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912